Page last updated: 2024-11-04

nafamostat

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Nafamostat mesilate, also known as FUT-175, is a synthetic serine protease inhibitor. It is a potent inhibitor of several serine proteases, including trypsin, plasmin, thrombin, and factor Xa. Nafamostat has been studied for its potential therapeutic effects in various diseases, including acute pancreatitis, disseminated intravascular coagulation (DIC), and viral infections. It inhibits the activation of coagulation factors, leading to anticoagulation. It is also known to have anti-inflammatory and anti-viral effects. It has shown promising activity against various viruses, including SARS-CoV-2, the virus responsible for COVID-19. The mechanism of action of Nafamostat in viral infections involves inhibiting viral entry and replication. It is currently being investigated in clinical trials as a potential treatment for COVID-19.'

nafamostat: inhibitor of trypsin, plasmin, pancreatic kallikrein, plasma kallikrein & thrombin; strongly inhibits esterolytic activities of C1r & C1 esterase complement-mediated hemolysis; antineoplastic [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID4413
CHEMBL ID273264
CHEBI ID135466
SCHEMBL ID135503
MeSH IDM0102244

Synonyms (53)

Synonym
NCGC00160398-01
nafamostat
BSPBIO_001194
NCGC00160398-02
nafamostat [inn]
benzoic acid, 4-((aminoiminomethyl)amino)-, 6-(aminoiminomethyl)-2-naphthalenyl ester
6-amidino2-naphthyl 4-guanidinobenzoate
6-(aminoiminomethyl)-2-naphthalenyl 4-((aminoiminomethyl)amino)benzoate
p-guanidinobenzoic acid ester with 6-hydroxy-2-naphthamidine
nafamostatum [latin]
NCGC00160398-03
CHEBI:135466
MLS-0435512.0001
CHEMBL273264 ,
81525-10-2
D08240
nafamostat (inn)
bdbm50063698
4-guanidino-benzoic acid 6-carbamimidoyl-naphthalen-2-yl ester(fut-175)
4-guanidino-benzoic acid 6-carbamimidoyl-naphthalen-2-yl ester
(6-carbamimidoylnaphthalen-2-yl) 4-(diaminomethylideneamino)benzoate
(6-carbamimidoyl-2-naphthyl) 4-guanidinobenzoate;nafamostat
A840154
NCGC00160398-04
ckd314
ckd-314
unii-y25lq0h97d
nafamostatum
y25lq0h97d ,
FT-0629861
AKOS017259237
nafabelltan
6-carbamimidoylnaphthalen-2-yl 4-[(diaminomethylidene)amino]benzoate
gtpl4262
HY-B0190
SCHEMBL135503
nafamostat [mi]
nafamostat [who-dd]
DTXSID0048420
6-amidino-2-naphthyl p-guanidinobenzoate
AB01566816_01
DB12598
6-carbamimidoylnaphthalen-2-yl 4-guanidinobenzoate
BS-17665
BCP13085
fut-175; fut 175; fut175
Q15409374
AMY8858
HMS3742K19
benzoic acid, 4-[(aminoiminomethyl)amino]-,6-(aminoiminomethyl)-2-naphthalenyl ester
NCGC00160398-13
7RF ,
(6-carbamimidoylnaphthalen-2-yl) 4-carbamimidamidobenzoate

Research Excerpts

Overview

Nafamostat is a serine protease inhibitor known to target thrombin. It has not been characterised for chemoprophylaxis in animal models. NafAmostat mesilate is a synthetic protease-inhibiting agent that has potent inhibitory activity.

ExcerptReferenceRelevance
"Nafamostat (NM) is a protease inhibitor approved for pancreatitis and anti-coagulation."( Nafamostat mesylate as a broad-spectrum candidate for the treatment of flavivirus infections by targeting envelope proteins.
Cao, R; Chen, X; Dai, Q; Guo, X; Li, W; Li, Y; Liu, M; Liu, Z; Ni, J; Ren, X; Song, M; Wang, C; Wang, Z; Xiao, D; Xu, Y; Yan, Y; Yang, J; Yang, X; Yin, J; Zhao, L; Zhong, W, 2022
)
2.89
"Nafamostat is an approved short-acting serine protease inhibitor. "( Nafamostat is a Potent Human Diamine Oxidase Inhibitor Possibly Augmenting Hypersensitivity Reactions during Nafamostat Administration.
Alix, M; Boehm, T; Borth, N; Gludovacz, E; Jilma, B; Petroczi, K; Salminen, TA; Vakal, S, 2022
)
3.61
"As nafamostat is a serine protease inhibitor known to target thrombin, we used argatroban (Arg), a thrombin-specific inhibitor, as a positive control in the time window experiments."( Delayed administration of nafamostat mesylate inhibits thrombin-mediated blood-spinal cord barrier breakdown during acute spinal cord injury in rats.
Fan, B; Feng, S; Kong, X; Li, M; Li, W; Liu, X; Ma, L; Pang, Y; Shen, W; Sun, C; Yao, X; Zhang, J; Zhao, C; Zhao, X; Zhou, T, 2022
)
1.54
"Nafamostat mesylate (NM) is a synthetic compound that inhibits various serine proteases produced during the coagulation cascade and inflammation. "( Structural study of the uPA-nafamostat complex reveals a covalent inhibitory mechanism of nafamostat.
Huang, M; Jiang, L; Li, J; Wu, J; Xue, G; Zhou, Y, 2022
)
2.46
"Nafamostat mesylate (NM) is a synthetic compound that inhibits various serine proteases and has been used as a therapeutic agent for the treatment of TNBC."( Nafamostat Mesylate in Combination with the Mouse Amino-Terminal Fragment of Urokinase-Human Serum Albumin Improves the Treatment Outcome of Triple-Negative Breast Cancer Therapy.
Chen, D; Huang, M; Jiang, L; Li, H; Xu, P; Yu, S; Yuan, C; Zhou, Y, 2023
)
3.07
"Nafamostat is a serine protease inhibitor that inhibits SARS-CoV-2 entry in vitro, but it has not been characterised for chemoprophylaxis in animal models."( Evaluation of Nafamostat as Chemoprophylaxis for SARS-CoV-2 Infection in Hamsters.
Arshad, U; Box, H; Bramwell, C; Cox, H; Curley, P; Dhaliwal, K; Gallardo-Toledo, E; Herriott, J; Hobson, J; Kijak, E; Kipar, A; Mc Caughan, F; Neary, M; Owen, A; Pertinez, H; Rajoli, RKR; Rannard, S; Sharp, J; Stewart, JP; Tatham, L; Valentijn, A, 2023
)
1.99
"Nafamostat mesilate is a serine protease inhibitor and used for the treatment of pancreatitis and cancers. "( Identification of nafamostat mesilate as an inhibitor of the fat mass and obesity-associated protein (FTO) demethylase activity.
Chang, J; Han, X; Li, J; Wang, N; Wang, R; Wang, Y, 2019
)
2.29
"Nafamostat mesilate (NM) is a synthetic protease-inhibiting agent that has not only potent inhibitory activity against coagulation factors (Xlla, Xa) but also an anti-inflammatory action."( Efficacy of nafamostat mesilate as anticoagulation during cardiopulmonary bypass for early surgery in patients with active infective endocarditis complicated by stroke.
Gotake, Y; Inoue, T; Izawa, N; Kano, H; Matsumori, M; Miyahara, S; Okada, K; Okita, Y; Sakamoto, T, 2014
)
1.5
"Nafamostat mesilate is an anti-inflammatory drug that is usually used to treat pancreatitis. "( Inhibition of the NF-κB pathway by nafamostat mesilate suppresses colorectal cancer growth and metastasis.
Chen, G; Chen, LZ; Ju, HQ; Kang, TB; Lu, YX; Mo, HY; Pan, ZZ; Sheng, H; Wang, F; Wu, QN; Xie, D; Xu, RH; Yun, JP; Zeng, ZL, 2016
)
2.15
"Nafamostat is a synthetic protease inhibitor with anticoagulant effects."( Nafamostat prevents hypothermia and improves survival time after administration of lipopolysaccharide in a mouse surgical model.
Adachi, YU; Doi, M; Itagaki, T; Katoh, H; Obata, Y; Sato, S; Suzuki, K, 2009
)
2.52
"Nafamostat mesilate (NM) is a guanidine acid derivative which is synthesized in Japan as an antifibrinolytic drug. "( Influence of heparin dosage on hemostasis under combined use of Nafamostat mesilate during deep hypothermic circulatory arrest.
Matsuyama, M; Nakamura, K; Niina, K; Onitsuka, T; Yano, M; Yano, Y, 2003
)
2
"Nafamostat mesilate (NM) is a serine-protease inhibitor that is rapidly eliminated from the circulation and accumulated in the kidney. "( Transporter-mediated renal handling of nafamostat mesilate.
Kato, Y; Li, Q; Muraoka, H; Sai, Y; Tamai, I; Tsuji, A, 2004
)
2.04
"Nafamostat Mesilate (NM) is a synthetic serine protease inhibitor that is capable of inhibiting the various coagulation factors. "( The role of a protease inhibitor against hepatectomy.
Gotohda, N; Iwagaki, H; Kinoshita, T; Konishi, M; Nakagohri, T; Ozaki, M; Takahashi, S; Tanaka, N; Yagi, T,
)
1.57
"Nafamostat mesilate (NM) is a synthetic protease inhibitor with various biological effects. "( Protective effects of nafamostat mesilate on liver injury induced by lipopolysaccharide in rats: possible involvement of CD14 and TLR-4 downregulation on Kupffer cells.
Choda, Y; Haga, S; Huda, K; Iwagaki, H; Katsuno, G; Miyaso, H; Morimoto, Y; Murata, H; Ozaki, M; Shinoura, S; Takahashi, H; Tanaka, N, 2006
)
2.09
"Nafamostat mesilate (NM) is a broad-range synthetic protease inhibitor with some anti-inflammatory action."( Nafamostat mesilate inhibits the expression of HMGB1 in lipopolysaccharide-induced acute lung injury.
Hagiwara, S; Iwasaka, H; Noguchi, T, 2007
)
2.5
"1. Nafamostat mesilate (NM) is a novel serine-protease inhibitor used for the treatment of acute pancreatitis and disseminated intravascular coagulation. "( Mechanisms of hyperkalemia caused by nafamostat mesilate.
Asano, Y; Imai, M; Muto, S, 1995
)
1.19
"Nafamostat mesilate (NM) is a synthetic protease inhibitor that is capable of inhibiting the various coagulation factors such as factor VIIa and thrombin. "( Effect of nafamostat mesilate on pulmonary vascular injury induced by lipopolysaccharide in rats.
Murakami, K; Okabe, H; Okajima, K; Takatsuki, K; Uchiba, M, 1997
)
2.14

Effects

Nafamostat mesylate has a similar profile of anti-coagulative activity to heparin. It has a protective effect against HBMVEC after exposure to thrombin and hypoxia.

Nafamostat has maximal effects on the pancreas and peritoneal capillary leakage when delivered by way of local intra-arterial infusion. It has a protective effect against HBMVEC after exposure to thrombin and hypoxia, suggesting its role in improving the neurological outcomes after SAH. Nafamstat has been widely used in acute blood purification at critical care units in Japan.

ExcerptReferenceRelevance
"Nafamostat has a protective effect against HBMVEC after exposure to thrombin and hypoxia, suggesting its role in improving the neurological outcomes after SAH."( Nafamostat protects against early brain injury after subarachnoid hemorrhage in mice.
Egashira, Y; Enomoto, Y; Hara, H; Imai, T; Iwama, T; Matsubara, H; Nakamura, S; Nakayama, N; Oka, N; Shimazawa, M; Tsuji, S, 2022
)
2.89
"Nafamostat mesylate has a similar profile of anti-coagulative activity to heparin. "( Superior outcome of nafamostat mesilate as an anticoagulant in patients undergoing maintenance hemodialysis with intracerebral hemorrhage.
Choi, SO; Han, BG; Kim, BR; Kim, YS; Lee, YH; Yang, JW; Yu, JM, 2009
)
2.12
"Nafamostat has a protective effect against HBMVEC after exposure to thrombin and hypoxia, suggesting its role in improving the neurological outcomes after SAH."( Nafamostat protects against early brain injury after subarachnoid hemorrhage in mice.
Egashira, Y; Enomoto, Y; Hara, H; Imai, T; Iwama, T; Matsubara, H; Nakamura, S; Nakayama, N; Oka, N; Shimazawa, M; Tsuji, S, 2022
)
2.89
"Nafamostat has been shown to have other, immunomodulatory effects, which may be beneficial for treatment, however animal models of ssRNA virus infection are lacking."( Nafamostat reduces systemic inflammation in TLR7-mediated virus-like illness.
Anthony, DC; Dunstan, IK; Strekalova, T; Weglinski, CM; Yates, AG; Ying, Y, 2022
)
2.89
"Nafamostat has recently been reported as a therapeutic agent for COVID-19."( Physical Compatibility of Nafamostat with Analgesics, Sedatives, and Muscle Relaxants for Treatment of Coronavirus Disease 2019.
Kondo, M; Nagano, M; Sugaya, K; Tagui, N; Takase, H; Yoshida, M; Yoshida, N, 2021
)
1.64
"Nafamostat mesylate has a similar profile of anti-coagulative activity to heparin. "( Superior outcome of nafamostat mesilate as an anticoagulant in patients undergoing maintenance hemodialysis with intracerebral hemorrhage.
Choi, SO; Han, BG; Kim, BR; Kim, YS; Lee, YH; Yang, JW; Yu, JM, 2009
)
2.12
"Nafamostat has been widely used in acute blood purification at critical care units in Japan."( Anticoagulation in acute blood purification for acute renal failure in critical care.
Shinoda, T, 2010
)
1.08
"Nafamostat has maximal effects on the pancreas and peritoneal capillary leakage when delivered by way of local intra-arterial infusion, and shows a greater reduction of lung leukocyte infiltration and capillary leakage by the intravenous route."( Regional effects of nafamostat, a novel potent protease and complement inhibitor, on severe necrotizing pancreatitis.
Antoniu, BA; Balcom, JH; Fernández-del Castillo, CF; Keck, T; Lewandrowski, K; Warshaw, AL, 2001
)
1.36

Actions

Nafamostat mesilate can suppress euglobulin lysis activity both intraoperatively and postoperatively, and thus decrease the amount of blood transfusion needed. NafAmostat may suppress the blood-foreign surface reaction similar to biocompatible materials by blocking factor XIIa.

ExcerptReferenceRelevance
"Nafamostat mesilate can suppress euglobulin lysis activity both intraoperatively and postoperatively, and thus decrease the amount of blood transfusion needed."( Effect of nafamostat mesilate on coagulation and fibrinolysis in hepatic resection.
Kamakura, T; Matsumata, T; Shimada, M; Shirabe, K; Sugimachi, K; Taketomi, A, 1994
)
1.41
"Nafamostat mesilate may suppress the blood-foreign surface reaction similar to biocompatible materials by blocking factor XIIa."( Nafamostat mesilate reduces blood-foreign surface reactions similar to biocompatible materials.
Hibi, M; Hiroura, M; Kawamura, M; Murakami, F; Murase, M; Ooshima, H; Tomita, Y; Usui, A; Yoshida, K, 1996
)
2.46
"Nafamostat group showed lower plasma dopamine levels and higher epinephrine levels compared with non-nafamostat group."( [Effect of nafamostat mesilate on serum activities of pancreatic enzymes and plasma hormone levels].
Matsuki, A; Sakai, T; Suzuki, T; Wakayama, S, 1990
)
1.39

Treatment

Nafamostat mesilate treatment significantly improved locomotion recovery as assessed by hindlimb BBB scores and the inclined plane test. Pretreatment with nafamstat reduced the titers of the pandemic and seasonal influenza viruses and the secretion of inflammatory cytokines.

ExcerptReferenceRelevance
"Nafamostat mesilate treatment significantly improved locomotion recovery as assessed by hindlimb BBB scores and the inclined plane test. "( Nafamostat mesilate attenuates inflammation and apoptosis and promotes locomotor recovery after spinal cord injury.
Duan, HQ; Fan, BY; Feng, SQ; Kong, XH; Li, B; Shi, HY; Sun, C; Wu, QL; Yao, X; Zhang, Y; Zhao, CX; Zhou, XF, 2018
)
3.37
"Nafamostat mesilate-treated animals had a lower transfusion requirement of shed blood, 18.1 +/- 4.5 mL/kg versus 30 +/- 0.43 mL/kg (p = 0.002)."( Inhibition of enteral enzymes by enteroclysis with nafamostat mesilate reduces neutrophil activation and transfusion requirements after hemorrhagic shock.
Coimbra, R; Doucet, JJ; Hoyt, DB; Hugli, TE; Junger, WG; Loomis, WH; Paul L, W; Schmid-Schönbein, GW, 2004
)
1.3
"Pretreatment with nafamostat reduced the titers of the pandemic and seasonal influenza viruses and the secretion of inflammatory cytokines, including interleukin-6 and tumor necrosis factor-α, in the supernatants of the cells infected with the pandemic influenza virus."( The clinically used serine protease inhibitor nafamostat reduces influenza virus replication and cytokine production in human airway epithelial cells and viral replication in mice.
Bazarragchaa, E; Kida, H; Nishimura, H; Ohkawara, A; Okamatsu, M; Sakoda, Y; Shimotai, Y; Yamaya, M, 2021
)
1.2
"Treatment with nafamostat mesilate significantly inhibited not only increased proteolytic activities, but also increases in the numbers of eosinophils and lymphocytes in the BALF."( Nafamostat mesilate, a potent serine protease inhibitor, inhibits airway eosinophilic inflammation and airway epithelial remodeling in a murine model of allergic asthma.
Inagaki, N; Ishizaki, M; Kajiwara, D; Nagai, H; Tanaka, H; Toyohara, T; Wakahara, K, 2008
)
2.13
"Pretreatment with nafamostat mesilate suppressed activation of p38 MAPK."( Effects of nafamostat mesilate on the prevention of cerulein-induced acute pancreatitis.
Jung, HC; Kim, YT; Lee, JK; Lee, SH; Park, JK; Ryu, JK; Yoon, WJ; Yoon, YB, 2008
)
1.06

Toxicity

The aim was to determine whether adverse effects of leukocytapheresis (LCAP) are related to nafamostat mesilate (NM) as an anticoagulant.

ExcerptReferenceRelevance
"The aim was to determine whether adverse effects of leukocytapheresis (LCAP) are related to nafamostat mesilate (NM) as an anticoagulant."( Detection of specific IgE antibodies to nafamostat mesilate as an indication of possible adverse effects of leukocytapheresis using nafamostat mesilate as anticoagulant.
Fukunaga, K; Kusaka, T; Matoba, Y; Nagase, K; Ohnishi, K; Sawada, K, 2004
)
0.81
" There were no significant differences in the incidence of adverse reactions (8."( Safety and Tolerability of Nafamostat Mesilate and Heparin as Anticoagulants in Leukocytapheresis for Ulcerative Colitis: Post Hoc Analysis of a Large-Scale, Prospective, Observational Study.
Hibi, T; Ino, T; Kusada, M; Nakamura, T; Numata, T; Ohdo, M; Sakou, J; Sawada, K; Shibata, H, 2016
)
0.73
"In hospitalised patients with COVID-19, we did not observe evidence of anti-inflammatory, anticoagulant or antiviral activity with intravenous nafamostat, and there were additional adverse events."( Randomised controlled trial of intravenous nafamostat mesylate in COVID pneumonitis: Phase 1b/2a experimental study to investigate safety, Pharmacokinetics and Pharmacodynamics.
Akram, AR; Anthony, DC; Antonelli, J; Blyth, KG; Boz, C; Bruce, A; Burgess, M; Church, C; Churchill, GC; Dear, JW; Dhaliwal, K; Dockrell, D; Duncan, A; Ebrahimi, KH; Emanuel, P; Ferrett, C; Findlay, EG; Finlayson, K; Gaughan, EE; Hardisty, G; Hirani, N; Jabbal, S; Koch, O; Li, F; MacKintosh, C; Marshall, ADL; McCullagh, JSO; McNamara, S; Mills, B; Mills, R; Moore, A; Nazarov, IB; Nimmo, AF; Norrie, J; O'Connor, R; Owen, A; Parker, RA; Plant, S; Quinn, TM; Rannard, S; Rinaldi, G; Russell, K; Scholefield, E; Schwarze, J; Shankar-Hari, M; Templeton, K; Valanciute, A; Walsh, T; Young, I, 2022
)
1.18
"Given the better survival outcomes, lower risk of bleeding, NM anticoagulation seems to be a safe and efficient approach for BPT patients and could yield a favorable filter lifespan."( Efficacy and safety of nafamostat mesilate anticoagulation in blood purification treatment of critically ill patients: a systematic review and meta-analysis.
He, J; Liao, S; Lin, Y; Liu, Y; Shao, Y; Xu, M; Yang, R; Yang, S, 2022
)
1.03
" No other serious adverse effects were observed."( Utility and safety of nafamostat mesilate for anticoagulation in dogs.
Isayama, N; Maeda, E; Matsumura, G; Sasaki, K; Uchimura, Y, 2023
)
1.22
"ACT results indicated that NM use in anaesthetised healthy dogs was sufficient to obtain procedural anticoagulation with minimal adverse effects."( Utility and safety of nafamostat mesilate for anticoagulation in dogs.
Isayama, N; Maeda, E; Matsumura, G; Sasaki, K; Uchimura, Y, 2023
)
1.22
" Serious adverse events were not observed in either group."( Antiviral effect and safety of nafamostat mesilate in patients with mild early-onset COVID-19: An exploratory multicentre randomized controlled clinical trial.
Hagiya, H; Harada, S; Hasegawa, K; Hashimoto, H; Ikeda, M; Ikeuchi, K; Imamura, A; Inoue, JI; Jubishi, D; Kashiwabara, K; Kisimoto, N; Kohsaka, T; Miwa, A; Mizoguchi, A; Moritoyo, T; Moriya, K; Okamoto, K; Okugawa, S; Otsuka, F; Seto, Y; Shimizu, T; Tsutsumi, T, 2023
)
1.2

Pharmacokinetics

ExcerptReferenceRelevance
" The pharmacokinetic parameters were also estimated and compared with those of Japanese volunteers (slightly lower plasma concentration and longer terminal elimination half-life for Chinese volunteers)."( A method for quantifying the unstable and highly polar drug nafamostat mesilate in human plasma with optimized solid-phase extraction and ESI-MS detection: more accurate evaluation for pharmacokinetic study.
Cao, YG; Chen, YC; Liu, XQ; Shao, JP; Yu, D; Zhang, M, 2008
)
0.59

Compound-Compound Interactions

The aim of this study was to investigate prognostic factors of survival for patients with unresectable pancreatic cancer treated with nafamostat mesilate combined with gemcitabine chemotherapy. Jaundice, ascites, high lymphocyte count and high serum CA19-9 levels are independent prognostic predictors for poor overall survival.

ExcerptReferenceRelevance
"To evaluate the efficacy of regional arterial infusion of the synthetic serine protease inhibitor nafamostat mesilate combined with gemcitabine for the treatment of patients with unresectable locally advanced or metastatic pancreatic cancer."( Phase II study of gemcitabine in combination with regional arterial infusion of nafamostat mesilate for advanced pancreatic cancer.
Gocho, T; Hirohara, S; Ito, R; Misawa, T; Sadaoka, S; Tsutsui, N; Uwagawa, T; Yanaga, K, 2013
)
0.83
"The aim of this study was to investigate prognostic factors of survival for patients with unresectable pancreatic cancer treated with nafamostat mesilate combined with gemcitabine chemotherapy."( Prognostic factors of unresectable pancreatic cancer treated with nafamostat mesilate combined with gemcitabine chemotherapy.
Fujiwara, Y; Furukawa, K; Gocho, T; Haruki, K; Iwase, R; Misawa, T; Shiba, H; Uwagawa, T; Yanaga, K, 2012
)
0.82
"The study included 41 patients who were diagnosed with unresectable pancreatic cancer and eligible for our clinical study of nafamostat mesilate, combined with gemcitabine chemotherapy for unresectable pancreatic cancer between February 2007 and November 2010 at Jikei University Hospital."( Prognostic factors of unresectable pancreatic cancer treated with nafamostat mesilate combined with gemcitabine chemotherapy.
Fujiwara, Y; Furukawa, K; Gocho, T; Haruki, K; Iwase, R; Misawa, T; Shiba, H; Uwagawa, T; Yanaga, K, 2012
)
0.82
"Jaundice, ascites, high lymphocyte count and high serum CA19-9 levels are independent prognostic predictors for poor overall survival of patients with unresectable pancreatic cancer treated with nafamostat mesilate combined with gemcitabine chemotherapy."( Prognostic factors of unresectable pancreatic cancer treated with nafamostat mesilate combined with gemcitabine chemotherapy.
Fujiwara, Y; Furukawa, K; Gocho, T; Haruki, K; Iwase, R; Misawa, T; Shiba, H; Uwagawa, T; Yanaga, K, 2012
)
0.81

Bioavailability

ExcerptReferenceRelevance
" It is produced as a latent complex and the main limiting step in TGFbeta bioavailability is its activation."( Tryptase activates TGFbeta in human airway smooth muscle cells via direct proteolysis.
Jenkins, G; Knox, A; Pang, L; Porte, J; Tatler, AL, 2008
)
0.35
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51

Dosage Studied

The study sought to determine whether intranasal dosing of nafamostat at 5 mg/kg twice daily was able to prevent the airborne transmission of SARS-CoV-2 from infected to uninfected Syrian Golden hamsters. The optimal concentrations of NCO-700 were 5 microM, 100 microM and 20 microM.

ExcerptRelevanceReference
" Post-ischemic recovery of AoF (%AoF) showed the bell-shaped dose-response curve, and the optimal dose was 3 microM (Exp."( [The effects of protease inhibitor upon the ischemia-reperfusion injury].
Kawashima, Y; Kinoshita, H; Nakajima, N; Ohashi, T; Shibata, T; Shimada, Y; Yamamoto, F, 1992
)
0.28
" The blood concentrations 3 min after dosing were less than 10(-6) M for all of the doses tested."( Inhibitory effect of nafamostat mesilate on metastasis into the livers of mice and on invasion of the extracellular matrix by cancer cells.
Fuchimoto, S; Hizuta, A; Iwagaki, H; Kimura, T; Orita, K, 1992
)
0.6
" These findings indicate that the stabilization of EGF at the wound site is an important factor in permitting the expression of its healing effects and suggest that the ointment containing EGF and a stabilizing agent would be a suitable dosage form for acceleration of wound repair."( Improvement in wound healing by epidermal growth factor (EGF) ointment. I. Effect of nafamostat, gabexate, or gelatin on stabilization and efficacy of EGF.
Fuwa, T; Hirai, M; Iwakawa, S; Kiyohara, Y; Komada, F; Okumura, K, 1990
)
0.5
", Forssman shock, Forssman cutaneous vasculitis, zymosan-induced paw edema, endotoxin shock and local Shwartzman reaction, FUT-175 was highly effective in that, for example, intravenous dosing at 3 mg/kg could completely protect guinea pigs from the lethal Forssman shock."( Pharmacological studies of FUT-175, nafamstat mesilate. I. Inhibition of protease activity in in vitro and in vivo experiments.
Aoyama, T; Fujita, M; Ino, Y; Koshiyama, Y; Oda, M; Ozeki, M; Sato, T; Suzuki, S, 1984
)
0.27
" FUT-175 significantly reduced heparin dosage and 24-hour postoperative blood loss (19,200 +/- 3200 versus 29,100 +/- 7700 IU, P < ."( Nafamostat mesilate reduces blood loss during open heart surgery.
Abe, T; Koyama, T; Maeda, M; Murase, M; Tomita, Y; Usui, A, 1993
)
1.73
" The dose-response characteristics of these three protease inhibitors were bell shaped, and the optimal concentrations of nafamostat mesilate, gabexate mesilate, and NCO-700 were 5 microM, 100 microM, and 20 microM, respectively."( Effects of protease inhibitors on postischemic recovery of the heart.
Kinoshita, H; Shibata, T; Suehiro, S; Yamamoto, F, 1997
)
0.5
" We investigated the ideal dosage and efficacy of nafamostat mesilate for use with ECMO in patients with acute cardiac or respiratory failure."( Use of nafamostat mesilate as an anticoagulant during extracorporeal membrane oxygenation.
Han, SJ; Hong, KS; Kim, HS; Kim, KI; Lee, SH; Lee, WK; Whang, SM, 2011
)
1.08
" Most units did not change the nutritional dosage according to CRRT use."( Characteristics of pediatric continuous renal replacement therapies in hospitals with pediatric intensive care units in Japan.
Haga, T; Ide, K; Tani, M, 2023
)
0.91
" This study sought to determine whether intranasal dosing of nafamostat at 5 mg/kg twice daily was able to prevent the airborne transmission of SARS-CoV-2 from infected to uninfected Syrian Golden hamsters."( Evaluation of Nafamostat as Chemoprophylaxis for SARS-CoV-2 Infection in Hamsters.
Arshad, U; Box, H; Bramwell, C; Cox, H; Curley, P; Dhaliwal, K; Gallardo-Toledo, E; Herriott, J; Hobson, J; Kijak, E; Kipar, A; Mc Caughan, F; Neary, M; Owen, A; Pertinez, H; Rajoli, RKR; Rannard, S; Sharp, J; Stewart, JP; Tatham, L; Valentijn, A, 2023
)
1.51
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (2)

ClassDescription
benzoic acidsAny aromatic carboxylic acid that consists of benzene in which at least a single hydrogen has been substituted by a carboxy group.
guanidinesAny organonitrogen compound containing a carbamimidamido (guanidino) group. Guanidines have the general structure (R(1)R(2)N)(R(3)R(4)N)C=N-R(5) and are related structurally to amidines and ureas.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (1)

PathwayProteinsCompounds
Nsp9 interactions (COVID-19 Disease Map)8330

Protein Targets (33)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Microtubule-associated protein tauHomo sapiens (human)Potency14.12540.180013.557439.8107AID1460
aldehyde dehydrogenase 1 family, member A1Homo sapiens (human)Potency22.38720.011212.4002100.0000AID1030
EWS/FLI fusion proteinHomo sapiens (human)Potency37.22120.001310.157742.8575AID1259253
vitamin D3 receptor isoform VDRAHomo sapiens (human)Potency100.00000.354828.065989.1251AID504847
lamin isoform A-delta10Homo sapiens (human)Potency0.00890.891312.067628.1838AID1487
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Ubiquitin-like modifier activating enzyme 2Homo sapiens (human)IC50 (µMol)7.47000.620016.325590.4600AID485393
SUMO1 activating enzyme subunit 1Homo sapiens (human)IC50 (µMol)7.47000.620016.325590.4600AID485393
ubiquitin-like modifier-activating enzyme 1Homo sapiens (human)IC50 (µMol)14.000014.000046.200078.4000AID2658
SUMO-conjugating enzyme UBC9Homo sapiens (human)IC50 (µMol)7.47000.620016.325590.4600AID485393
ubiquitin-conjugating enzyme E2 NHomo sapiens (human)IC50 (µMol)14.00000.873010.721978.4000AID2658
ubiquitin-conjugating enzyme E2 variant 1 isoform aHomo sapiens (human)IC50 (µMol)14.000014.000046.200078.4000AID2658
ProthrombinHomo sapiens (human)IC50 (µMol)1.90000.00000.710710.0000AID211559
Complement C1r subcomponentHomo sapiens (human)IC50 (µMol)9.76000.80000.80000.8000AID1393211; AID43030; AID43031; AID50879; AID50880
Coagulation factor XHomo sapiens (human)IC50 (µMol)21.10000.00030.593710.0000AID51836
PlasminogenHomo sapiens (human)IC50 (µMol)2.90000.02503.628010.0000AID225429
PlasminogenHomo sapiens (human)Ki0.41000.01701.15604.4000AID1558664
Coagulation factor XIIHomo sapiens (human)Ki0.10500.00251.86697.2500AID1705180
Cationic trypsinBos taurus (cattle)IC50 (µMol)0.01700.00003.479210.0000AID215034
Interstitial collagenaseHomo sapiens (human)IC50 (µMol)420.00000.00020.850210.0000AID52486
Integrin beta-3Homo sapiens (human)IC50 (µMol)12.00000.00010.632310.0000AID1480447
Serine protease hepsinHomo sapiens (human)IC50 (µMol)0.00500.00500.10870.3830AID1495527
Serine protease hepsinHomo sapiens (human)Ki0.00050.00050.19170.8350AID1171341; AID1195363
Cathepsin DHomo sapiens (human)IC50 (µMol)1,000.00000.00000.931610.0000AID48013
Trypsin-1Homo sapiens (human)IC50 (µMol)0.01700.00351.532110.0000AID215021
72 kDa type IV collagenaseHomo sapiens (human)IC50 (µMol)420.00000.00001.284810.0000AID52486
Integrin alpha-IIbHomo sapiens (human)IC50 (µMol)12.00000.00010.730910.0000AID1480447
5-hydroxytryptamine receptor 2CRattus norvegicus (Norway rat)IC50 (µMol)12.00000.00040.629810.0000AID50879
Complement C1s subcomponentHomo sapiens (human)IC50 (µMol)0.02900.02900.02900.0290AID1393212
Matrix metalloproteinase-9Homo sapiens (human)IC50 (µMol)420.00000.00000.705310.0000AID52486
5-hydroxytryptamine receptor 2ARattus norvegicus (Norway rat)IC50 (µMol)12.00000.00040.908610.0000AID50879
Neutrophil collagenaseHomo sapiens (human)IC50 (µMol)420.00000.00000.927210.0000AID52486
5-hydroxytryptamine receptor 2BRattus norvegicus (Norway rat)IC50 (µMol)12.00000.00040.615610.0000AID50879
Collagenase 3Homo sapiens (human)IC50 (µMol)420.00000.00000.767510.0000AID52486
Hepatocyte growth factor activatorHomo sapiens (human)IC50 (µMol)0.15000.15000.48500.8200AID1195360
Hepatocyte growth factor activatorHomo sapiens (human)Ki0.02500.02500.07930.1880AID1171339; AID1195361
Suppressor of tumorigenicity 14 proteinHomo sapiens (human)Ki0.00000.00000.87113.3500AID1171340; AID1195362
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Hepatocyte growth factor activatorHomo sapiens (human)EC50 (µMol)0.49000.49000.49000.4900AID1171348
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (214)

Processvia Protein(s)Taxonomy
positive regulation of protein phosphorylationProthrombinHomo sapiens (human)
proteolysisProthrombinHomo sapiens (human)
acute-phase responseProthrombinHomo sapiens (human)
cell surface receptor signaling pathwayProthrombinHomo sapiens (human)
G protein-coupled receptor signaling pathwayProthrombinHomo sapiens (human)
blood coagulationProthrombinHomo sapiens (human)
positive regulation of cell population proliferationProthrombinHomo sapiens (human)
regulation of cell shapeProthrombinHomo sapiens (human)
response to woundingProthrombinHomo sapiens (human)
negative regulation of platelet activationProthrombinHomo sapiens (human)
platelet activationProthrombinHomo sapiens (human)
regulation of blood coagulationProthrombinHomo sapiens (human)
positive regulation of blood coagulationProthrombinHomo sapiens (human)
positive regulation of cell growthProthrombinHomo sapiens (human)
positive regulation of insulin secretionProthrombinHomo sapiens (human)
positive regulation of collagen biosynthetic processProthrombinHomo sapiens (human)
fibrinolysisProthrombinHomo sapiens (human)
negative regulation of proteolysisProthrombinHomo sapiens (human)
positive regulation of receptor signaling pathway via JAK-STATProthrombinHomo sapiens (human)
negative regulation of astrocyte differentiationProthrombinHomo sapiens (human)
positive regulation of release of sequestered calcium ion into cytosolProthrombinHomo sapiens (human)
regulation of cytosolic calcium ion concentrationProthrombinHomo sapiens (human)
cytolysis by host of symbiont cellsProthrombinHomo sapiens (human)
positive regulation of phosphatidylinositol 3-kinase/protein kinase B signal transductionProthrombinHomo sapiens (human)
negative regulation of fibrinolysisProthrombinHomo sapiens (human)
antimicrobial humoral immune response mediated by antimicrobial peptideProthrombinHomo sapiens (human)
neutrophil-mediated killing of gram-negative bacteriumProthrombinHomo sapiens (human)
positive regulation of lipid kinase activityProthrombinHomo sapiens (human)
negative regulation of cytokine production involved in inflammatory responseProthrombinHomo sapiens (human)
positive regulation of protein localization to nucleusProthrombinHomo sapiens (human)
positive regulation of phospholipase C-activating G protein-coupled receptor signaling pathwayProthrombinHomo sapiens (human)
ligand-gated ion channel signaling pathwayProthrombinHomo sapiens (human)
positive regulation of reactive oxygen species metabolic processProthrombinHomo sapiens (human)
immune responseComplement C1r subcomponentHomo sapiens (human)
complement activation, classical pathwayComplement C1r subcomponentHomo sapiens (human)
zymogen activationComplement C1r subcomponentHomo sapiens (human)
innate immune responseComplement C1r subcomponentHomo sapiens (human)
proteolysisCoagulation factor XHomo sapiens (human)
blood coagulationCoagulation factor XHomo sapiens (human)
positive regulation of cell migrationCoagulation factor XHomo sapiens (human)
positive regulation of TOR signalingCoagulation factor XHomo sapiens (human)
proteolysisPlasminogenHomo sapiens (human)
blood coagulationPlasminogenHomo sapiens (human)
negative regulation of cell population proliferationPlasminogenHomo sapiens (human)
negative regulation of cell-substrate adhesionPlasminogenHomo sapiens (human)
extracellular matrix disassemblyPlasminogenHomo sapiens (human)
tissue regenerationPlasminogenHomo sapiens (human)
fibrinolysisPlasminogenHomo sapiens (human)
positive regulation of blood vessel endothelial cell migrationPlasminogenHomo sapiens (human)
myoblast differentiationPlasminogenHomo sapiens (human)
muscle cell cellular homeostasisPlasminogenHomo sapiens (human)
tissue remodelingPlasminogenHomo sapiens (human)
biological process involved in interaction with symbiontPlasminogenHomo sapiens (human)
negative regulation of fibrinolysisPlasminogenHomo sapiens (human)
positive regulation of fibrinolysisPlasminogenHomo sapiens (human)
trophoblast giant cell differentiationPlasminogenHomo sapiens (human)
labyrinthine layer blood vessel developmentPlasminogenHomo sapiens (human)
mononuclear cell migrationPlasminogenHomo sapiens (human)
trans-synaptic signaling by BDNF, modulating synaptic transmissionPlasminogenHomo sapiens (human)
negative regulation of cell-cell adhesion mediated by cadherinPlasminogenHomo sapiens (human)
plasma kallikrein-kinin cascadeCoagulation factor XIIHomo sapiens (human)
Factor XII activationCoagulation factor XIIHomo sapiens (human)
blood coagulation, intrinsic pathwayCoagulation factor XIIHomo sapiens (human)
positive regulation of plasminogen activationCoagulation factor XIIHomo sapiens (human)
protein processingCoagulation factor XIIHomo sapiens (human)
protein autoprocessingCoagulation factor XIIHomo sapiens (human)
positive regulation of blood coagulationCoagulation factor XIIHomo sapiens (human)
zymogen activationCoagulation factor XIIHomo sapiens (human)
fibrinolysisCoagulation factor XIIHomo sapiens (human)
innate immune responseCoagulation factor XIIHomo sapiens (human)
response to misfolded proteinCoagulation factor XIIHomo sapiens (human)
positive regulation of fibrinolysisCoagulation factor XIIHomo sapiens (human)
blood coagulationCoagulation factor XIIHomo sapiens (human)
proteolysisCationic trypsinBos taurus (cattle)
digestionCationic trypsinBos taurus (cattle)
proteolysisInterstitial collagenaseHomo sapiens (human)
protein metabolic processInterstitial collagenaseHomo sapiens (human)
extracellular matrix disassemblyInterstitial collagenaseHomo sapiens (human)
collagen catabolic processInterstitial collagenaseHomo sapiens (human)
positive regulation of protein-containing complex assemblyInterstitial collagenaseHomo sapiens (human)
cellular response to UV-AInterstitial collagenaseHomo sapiens (human)
extracellular matrix organizationInterstitial collagenaseHomo sapiens (human)
negative regulation of low-density lipoprotein receptor activityIntegrin beta-3Homo sapiens (human)
positive regulation of protein phosphorylationIntegrin beta-3Homo sapiens (human)
positive regulation of endothelial cell proliferationIntegrin beta-3Homo sapiens (human)
positive regulation of cell-matrix adhesionIntegrin beta-3Homo sapiens (human)
cell-substrate junction assemblyIntegrin beta-3Homo sapiens (human)
cell adhesionIntegrin beta-3Homo sapiens (human)
cell-matrix adhesionIntegrin beta-3Homo sapiens (human)
integrin-mediated signaling pathwayIntegrin beta-3Homo sapiens (human)
embryo implantationIntegrin beta-3Homo sapiens (human)
blood coagulationIntegrin beta-3Homo sapiens (human)
positive regulation of endothelial cell migrationIntegrin beta-3Homo sapiens (human)
positive regulation of gene expressionIntegrin beta-3Homo sapiens (human)
negative regulation of macrophage derived foam cell differentiationIntegrin beta-3Homo sapiens (human)
positive regulation of fibroblast migrationIntegrin beta-3Homo sapiens (human)
negative regulation of lipid storageIntegrin beta-3Homo sapiens (human)
response to activityIntegrin beta-3Homo sapiens (human)
smooth muscle cell migrationIntegrin beta-3Homo sapiens (human)
positive regulation of smooth muscle cell migrationIntegrin beta-3Homo sapiens (human)
platelet activationIntegrin beta-3Homo sapiens (human)
positive regulation of vascular endothelial growth factor receptor signaling pathwayIntegrin beta-3Homo sapiens (human)
cell-substrate adhesionIntegrin beta-3Homo sapiens (human)
activation of protein kinase activityIntegrin beta-3Homo sapiens (human)
negative regulation of lipid transportIntegrin beta-3Homo sapiens (human)
regulation of protein localizationIntegrin beta-3Homo sapiens (human)
regulation of actin cytoskeleton organizationIntegrin beta-3Homo sapiens (human)
cell adhesion mediated by integrinIntegrin beta-3Homo sapiens (human)
positive regulation of cell adhesion mediated by integrinIntegrin beta-3Homo sapiens (human)
positive regulation of osteoblast proliferationIntegrin beta-3Homo sapiens (human)
heterotypic cell-cell adhesionIntegrin beta-3Homo sapiens (human)
substrate adhesion-dependent cell spreadingIntegrin beta-3Homo sapiens (human)
tube developmentIntegrin beta-3Homo sapiens (human)
wound healing, spreading of epidermal cellsIntegrin beta-3Homo sapiens (human)
cellular response to platelet-derived growth factor stimulusIntegrin beta-3Homo sapiens (human)
apolipoprotein A-I-mediated signaling pathwayIntegrin beta-3Homo sapiens (human)
wound healingIntegrin beta-3Homo sapiens (human)
apoptotic cell clearanceIntegrin beta-3Homo sapiens (human)
regulation of bone resorptionIntegrin beta-3Homo sapiens (human)
positive regulation of angiogenesisIntegrin beta-3Homo sapiens (human)
positive regulation of bone resorptionIntegrin beta-3Homo sapiens (human)
symbiont entry into host cellIntegrin beta-3Homo sapiens (human)
platelet-derived growth factor receptor signaling pathwayIntegrin beta-3Homo sapiens (human)
positive regulation of fibroblast proliferationIntegrin beta-3Homo sapiens (human)
mesodermal cell differentiationIntegrin beta-3Homo sapiens (human)
positive regulation of smooth muscle cell proliferationIntegrin beta-3Homo sapiens (human)
positive regulation of peptidyl-tyrosine phosphorylationIntegrin beta-3Homo sapiens (human)
negative regulation of lipoprotein metabolic processIntegrin beta-3Homo sapiens (human)
negative chemotaxisIntegrin beta-3Homo sapiens (human)
regulation of release of sequestered calcium ion into cytosolIntegrin beta-3Homo sapiens (human)
regulation of serotonin uptakeIntegrin beta-3Homo sapiens (human)
angiogenesis involved in wound healingIntegrin beta-3Homo sapiens (human)
positive regulation of ERK1 and ERK2 cascadeIntegrin beta-3Homo sapiens (human)
platelet aggregationIntegrin beta-3Homo sapiens (human)
cellular response to mechanical stimulusIntegrin beta-3Homo sapiens (human)
cellular response to xenobiotic stimulusIntegrin beta-3Homo sapiens (human)
positive regulation of glomerular mesangial cell proliferationIntegrin beta-3Homo sapiens (human)
blood coagulation, fibrin clot formationIntegrin beta-3Homo sapiens (human)
maintenance of postsynaptic specialization structureIntegrin beta-3Homo sapiens (human)
regulation of postsynaptic neurotransmitter receptor internalizationIntegrin beta-3Homo sapiens (human)
regulation of postsynaptic neurotransmitter receptor diffusion trappingIntegrin beta-3Homo sapiens (human)
positive regulation of substrate adhesion-dependent cell spreadingIntegrin beta-3Homo sapiens (human)
positive regulation of adenylate cyclase-inhibiting opioid receptor signaling pathwayIntegrin beta-3Homo sapiens (human)
regulation of trophoblast cell migrationIntegrin beta-3Homo sapiens (human)
regulation of extracellular matrix organizationIntegrin beta-3Homo sapiens (human)
cellular response to insulin-like growth factor stimulusIntegrin beta-3Homo sapiens (human)
negative regulation of endothelial cell apoptotic processIntegrin beta-3Homo sapiens (human)
positive regulation of T cell migrationIntegrin beta-3Homo sapiens (human)
cell migrationIntegrin beta-3Homo sapiens (human)
proteolysisSerine protease hepsinHomo sapiens (human)
regulation of cell shapeSerine protease hepsinHomo sapiens (human)
positive regulation of gene expressionSerine protease hepsinHomo sapiens (human)
negative regulation of epithelial to mesenchymal transitionSerine protease hepsinHomo sapiens (human)
positive regulation of plasminogen activationSerine protease hepsinHomo sapiens (human)
positive regulation of cell growthSerine protease hepsinHomo sapiens (human)
basement membrane disassemblySerine protease hepsinHomo sapiens (human)
negative regulation of apoptotic processSerine protease hepsinHomo sapiens (human)
positive regulation by host of viral transcriptionSerine protease hepsinHomo sapiens (human)
negative regulation of epithelial cell proliferationSerine protease hepsinHomo sapiens (human)
detection of mechanical stimulus involved in sensory perception of soundSerine protease hepsinHomo sapiens (human)
potassium ion transmembrane transportSerine protease hepsinHomo sapiens (human)
cochlea morphogenesisSerine protease hepsinHomo sapiens (human)
response to thyroid hormoneSerine protease hepsinHomo sapiens (human)
pilomotor reflexSerine protease hepsinHomo sapiens (human)
positive regulation of hepatocyte proliferationSerine protease hepsinHomo sapiens (human)
positive regulation of thyroid hormone generationSerine protease hepsinHomo sapiens (human)
autophagosome assemblyCathepsin DHomo sapiens (human)
proteolysisCathepsin DHomo sapiens (human)
antigen processing and presentation of exogenous peptide antigen via MHC class IICathepsin DHomo sapiens (human)
insulin receptor recyclingCathepsin DHomo sapiens (human)
lipoprotein catabolic processCathepsin DHomo sapiens (human)
positive regulation of apoptotic processCathepsin DHomo sapiens (human)
positive regulation of cysteine-type endopeptidase activity involved in apoptotic processCathepsin DHomo sapiens (human)
regulation of establishment of protein localizationCathepsin DHomo sapiens (human)
insulin catabolic processCathepsin DHomo sapiens (human)
digestionTrypsin-1Homo sapiens (human)
extracellular matrix disassemblyTrypsin-1Homo sapiens (human)
proteolysisTrypsin-1Homo sapiens (human)
angiogenesis72 kDa type IV collagenaseHomo sapiens (human)
ovarian follicle development72 kDa type IV collagenaseHomo sapiens (human)
ovulation from ovarian follicle72 kDa type IV collagenaseHomo sapiens (human)
luteinization72 kDa type IV collagenaseHomo sapiens (human)
blood vessel maturation72 kDa type IV collagenaseHomo sapiens (human)
intramembranous ossification72 kDa type IV collagenaseHomo sapiens (human)
proteolysis72 kDa type IV collagenaseHomo sapiens (human)
negative regulation of cell adhesion72 kDa type IV collagenaseHomo sapiens (human)
heart development72 kDa type IV collagenaseHomo sapiens (human)
embryo implantation72 kDa type IV collagenaseHomo sapiens (human)
parturition72 kDa type IV collagenaseHomo sapiens (human)
response to xenobiotic stimulus72 kDa type IV collagenaseHomo sapiens (human)
response to mechanical stimulus72 kDa type IV collagenaseHomo sapiens (human)
peripheral nervous system axon regeneration72 kDa type IV collagenaseHomo sapiens (human)
response to activity72 kDa type IV collagenaseHomo sapiens (human)
protein metabolic process72 kDa type IV collagenaseHomo sapiens (human)
extracellular matrix disassembly72 kDa type IV collagenaseHomo sapiens (human)
protein catabolic process72 kDa type IV collagenaseHomo sapiens (human)
positive regulation of cell migration72 kDa type IV collagenaseHomo sapiens (human)
collagen catabolic process72 kDa type IV collagenaseHomo sapiens (human)
response to retinoic acid72 kDa type IV collagenaseHomo sapiens (human)
cellular response to reactive oxygen species72 kDa type IV collagenaseHomo sapiens (human)
response to nicotine72 kDa type IV collagenaseHomo sapiens (human)
endodermal cell differentiation72 kDa type IV collagenaseHomo sapiens (human)
response to hydrogen peroxide72 kDa type IV collagenaseHomo sapiens (human)
response to estrogen72 kDa type IV collagenaseHomo sapiens (human)
negative regulation of vasoconstriction72 kDa type IV collagenaseHomo sapiens (human)
ephrin receptor signaling pathway72 kDa type IV collagenaseHomo sapiens (human)
macrophage chemotaxis72 kDa type IV collagenaseHomo sapiens (human)
response to electrical stimulus72 kDa type IV collagenaseHomo sapiens (human)
response to hyperoxia72 kDa type IV collagenaseHomo sapiens (human)
face morphogenesis72 kDa type IV collagenaseHomo sapiens (human)
bone trabecula formation72 kDa type IV collagenaseHomo sapiens (human)
prostate gland epithelium morphogenesis72 kDa type IV collagenaseHomo sapiens (human)
cellular response to amino acid stimulus72 kDa type IV collagenaseHomo sapiens (human)
cellular response to interleukin-172 kDa type IV collagenaseHomo sapiens (human)
cellular response to estradiol stimulus72 kDa type IV collagenaseHomo sapiens (human)
cellular response to UV-A72 kDa type IV collagenaseHomo sapiens (human)
cellular response to fluid shear stress72 kDa type IV collagenaseHomo sapiens (human)
positive regulation of oxidative stress-induced neuron intrinsic apoptotic signaling pathway72 kDa type IV collagenaseHomo sapiens (human)
response to amyloid-beta72 kDa type IV collagenaseHomo sapiens (human)
positive regulation of vascular associated smooth muscle cell proliferation72 kDa type IV collagenaseHomo sapiens (human)
extracellular matrix organization72 kDa type IV collagenaseHomo sapiens (human)
response to hypoxia72 kDa type IV collagenaseHomo sapiens (human)
tissue remodeling72 kDa type IV collagenaseHomo sapiens (human)
positive regulation of leukocyte migrationIntegrin alpha-IIbHomo sapiens (human)
cell-matrix adhesionIntegrin alpha-IIbHomo sapiens (human)
integrin-mediated signaling pathwayIntegrin alpha-IIbHomo sapiens (human)
angiogenesisIntegrin alpha-IIbHomo sapiens (human)
cell-cell adhesionIntegrin alpha-IIbHomo sapiens (human)
cell adhesion mediated by integrinIntegrin alpha-IIbHomo sapiens (human)
proteolysisComplement C1s subcomponentHomo sapiens (human)
complement activation, classical pathwayComplement C1s subcomponentHomo sapiens (human)
innate immune responseComplement C1s subcomponentHomo sapiens (human)
skeletal system developmentMatrix metalloproteinase-9Homo sapiens (human)
positive regulation of protein phosphorylationMatrix metalloproteinase-9Homo sapiens (human)
proteolysisMatrix metalloproteinase-9Homo sapiens (human)
apoptotic processMatrix metalloproteinase-9Homo sapiens (human)
embryo implantationMatrix metalloproteinase-9Homo sapiens (human)
cell migrationMatrix metalloproteinase-9Homo sapiens (human)
extracellular matrix disassemblyMatrix metalloproteinase-9Homo sapiens (human)
macrophage differentiationMatrix metalloproteinase-9Homo sapiens (human)
collagen catabolic processMatrix metalloproteinase-9Homo sapiens (human)
cellular response to reactive oxygen speciesMatrix metalloproteinase-9Homo sapiens (human)
endodermal cell differentiationMatrix metalloproteinase-9Homo sapiens (human)
positive regulation of apoptotic processMatrix metalloproteinase-9Homo sapiens (human)
negative regulation of apoptotic processMatrix metalloproteinase-9Homo sapiens (human)
positive regulation of DNA bindingMatrix metalloproteinase-9Homo sapiens (human)
positive regulation of epidermal growth factor receptor signaling pathwayMatrix metalloproteinase-9Homo sapiens (human)
ephrin receptor signaling pathwayMatrix metalloproteinase-9Homo sapiens (human)
positive regulation of keratinocyte migrationMatrix metalloproteinase-9Homo sapiens (human)
cellular response to lipopolysaccharideMatrix metalloproteinase-9Homo sapiens (human)
cellular response to cadmium ionMatrix metalloproteinase-9Homo sapiens (human)
cellular response to UV-AMatrix metalloproteinase-9Homo sapiens (human)
positive regulation of release of cytochrome c from mitochondriaMatrix metalloproteinase-9Homo sapiens (human)
regulation of neuroinflammatory responseMatrix metalloproteinase-9Homo sapiens (human)
positive regulation of receptor bindingMatrix metalloproteinase-9Homo sapiens (human)
response to amyloid-betaMatrix metalloproteinase-9Homo sapiens (human)
positive regulation of vascular associated smooth muscle cell proliferationMatrix metalloproteinase-9Homo sapiens (human)
negative regulation of epithelial cell differentiation involved in kidney developmentMatrix metalloproteinase-9Homo sapiens (human)
negative regulation of intrinsic apoptotic signaling pathwayMatrix metalloproteinase-9Homo sapiens (human)
negative regulation of cation channel activityMatrix metalloproteinase-9Homo sapiens (human)
negative regulation of cysteine-type endopeptidase activity involved in apoptotic signaling pathwayMatrix metalloproteinase-9Homo sapiens (human)
extracellular matrix organizationMatrix metalloproteinase-9Homo sapiens (human)
positive regulation of microglial cell activationNeutrophil collagenaseHomo sapiens (human)
proteolysisNeutrophil collagenaseHomo sapiens (human)
extracellular matrix disassemblyNeutrophil collagenaseHomo sapiens (human)
collagen catabolic processNeutrophil collagenaseHomo sapiens (human)
positive regulation of tumor necrosis factor productionNeutrophil collagenaseHomo sapiens (human)
endodermal cell differentiationNeutrophil collagenaseHomo sapiens (human)
cellular response to lipopolysaccharideNeutrophil collagenaseHomo sapiens (human)
positive regulation of neuroinflammatory responseNeutrophil collagenaseHomo sapiens (human)
positive regulation of tumor necrosis factor-mediated signaling pathwayNeutrophil collagenaseHomo sapiens (human)
extracellular matrix organizationNeutrophil collagenaseHomo sapiens (human)
endochondral ossificationCollagenase 3Homo sapiens (human)
growth plate cartilage developmentCollagenase 3Homo sapiens (human)
proteolysisCollagenase 3Homo sapiens (human)
extracellular matrix disassemblyCollagenase 3Homo sapiens (human)
bone mineralizationCollagenase 3Homo sapiens (human)
collagen catabolic processCollagenase 3Homo sapiens (human)
bone morphogenesisCollagenase 3Homo sapiens (human)
response to amyloid-betaCollagenase 3Homo sapiens (human)
extracellular matrix organizationCollagenase 3Homo sapiens (human)
proteolysisHepatocyte growth factor activatorHomo sapiens (human)
blood coagulationHepatocyte growth factor activatorHomo sapiens (human)
zymogen activationHepatocyte growth factor activatorHomo sapiens (human)
neural tube closureSuppressor of tumorigenicity 14 proteinHomo sapiens (human)
proteolysisSuppressor of tumorigenicity 14 proteinHomo sapiens (human)
protein catabolic processSuppressor of tumorigenicity 14 proteinHomo sapiens (human)
keratinocyte differentiationSuppressor of tumorigenicity 14 proteinHomo sapiens (human)
epithelial cell morphogenesis involved in placental branchingSuppressor of tumorigenicity 14 proteinHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (49)

Processvia Protein(s)Taxonomy
lipopolysaccharide bindingProthrombinHomo sapiens (human)
serine-type endopeptidase activityProthrombinHomo sapiens (human)
signaling receptor bindingProthrombinHomo sapiens (human)
calcium ion bindingProthrombinHomo sapiens (human)
protein bindingProthrombinHomo sapiens (human)
growth factor activityProthrombinHomo sapiens (human)
heparin bindingProthrombinHomo sapiens (human)
thrombospondin receptor activityProthrombinHomo sapiens (human)
serine-type endopeptidase activityComplement C1r subcomponentHomo sapiens (human)
calcium ion bindingComplement C1r subcomponentHomo sapiens (human)
protein bindingComplement C1r subcomponentHomo sapiens (human)
serine-type peptidase activityComplement C1r subcomponentHomo sapiens (human)
identical protein bindingComplement C1r subcomponentHomo sapiens (human)
molecular sequestering activityComplement C1r subcomponentHomo sapiens (human)
serine-type endopeptidase activityCoagulation factor XHomo sapiens (human)
calcium ion bindingCoagulation factor XHomo sapiens (human)
protein bindingCoagulation factor XHomo sapiens (human)
phospholipid bindingCoagulation factor XHomo sapiens (human)
protease bindingPlasminogenHomo sapiens (human)
endopeptidase activityPlasminogenHomo sapiens (human)
serine-type endopeptidase activityPlasminogenHomo sapiens (human)
signaling receptor bindingPlasminogenHomo sapiens (human)
protein bindingPlasminogenHomo sapiens (human)
serine-type peptidase activityPlasminogenHomo sapiens (human)
enzyme bindingPlasminogenHomo sapiens (human)
kinase bindingPlasminogenHomo sapiens (human)
protein domain specific bindingPlasminogenHomo sapiens (human)
apolipoprotein bindingPlasminogenHomo sapiens (human)
protein-folding chaperone bindingPlasminogenHomo sapiens (human)
protein antigen bindingPlasminogenHomo sapiens (human)
serine-type endopeptidase activityCoagulation factor XIIHomo sapiens (human)
calcium ion bindingCoagulation factor XIIHomo sapiens (human)
protein bindingCoagulation factor XIIHomo sapiens (human)
misfolded protein bindingCoagulation factor XIIHomo sapiens (human)
endopeptidase activityCationic trypsinBos taurus (cattle)
serine-type endopeptidase activityCationic trypsinBos taurus (cattle)
protein bindingCationic trypsinBos taurus (cattle)
metal ion bindingCationic trypsinBos taurus (cattle)
serpin family protein bindingCationic trypsinBos taurus (cattle)
endopeptidase activityInterstitial collagenaseHomo sapiens (human)
metalloendopeptidase activityInterstitial collagenaseHomo sapiens (human)
serine-type endopeptidase activityInterstitial collagenaseHomo sapiens (human)
peptidase activityInterstitial collagenaseHomo sapiens (human)
zinc ion bindingInterstitial collagenaseHomo sapiens (human)
fibroblast growth factor bindingIntegrin beta-3Homo sapiens (human)
C-X3-C chemokine bindingIntegrin beta-3Homo sapiens (human)
insulin-like growth factor I bindingIntegrin beta-3Homo sapiens (human)
neuregulin bindingIntegrin beta-3Homo sapiens (human)
virus receptor activityIntegrin beta-3Homo sapiens (human)
fibronectin bindingIntegrin beta-3Homo sapiens (human)
protease bindingIntegrin beta-3Homo sapiens (human)
protein disulfide isomerase activityIntegrin beta-3Homo sapiens (human)
protein kinase C bindingIntegrin beta-3Homo sapiens (human)
platelet-derived growth factor receptor bindingIntegrin beta-3Homo sapiens (human)
integrin bindingIntegrin beta-3Homo sapiens (human)
protein bindingIntegrin beta-3Homo sapiens (human)
coreceptor activityIntegrin beta-3Homo sapiens (human)
enzyme bindingIntegrin beta-3Homo sapiens (human)
identical protein bindingIntegrin beta-3Homo sapiens (human)
vascular endothelial growth factor receptor 2 bindingIntegrin beta-3Homo sapiens (human)
metal ion bindingIntegrin beta-3Homo sapiens (human)
cell adhesion molecule bindingIntegrin beta-3Homo sapiens (human)
extracellular matrix bindingIntegrin beta-3Homo sapiens (human)
fibrinogen bindingIntegrin beta-3Homo sapiens (human)
serine-type endopeptidase activitySerine protease hepsinHomo sapiens (human)
protein bindingSerine protease hepsinHomo sapiens (human)
peptidase activitySerine protease hepsinHomo sapiens (human)
serine-type peptidase activitySerine protease hepsinHomo sapiens (human)
serine-type exopeptidase activitySerine protease hepsinHomo sapiens (human)
cysteine-type endopeptidase activityCathepsin DHomo sapiens (human)
protein bindingCathepsin DHomo sapiens (human)
peptidase activityCathepsin DHomo sapiens (human)
aspartic-type peptidase activityCathepsin DHomo sapiens (human)
aspartic-type endopeptidase activityCathepsin DHomo sapiens (human)
serine-type endopeptidase activityTrypsin-1Homo sapiens (human)
metal ion bindingTrypsin-1Homo sapiens (human)
fibronectin binding72 kDa type IV collagenaseHomo sapiens (human)
endopeptidase activity72 kDa type IV collagenaseHomo sapiens (human)
metalloendopeptidase activity72 kDa type IV collagenaseHomo sapiens (human)
serine-type endopeptidase activity72 kDa type IV collagenaseHomo sapiens (human)
protein binding72 kDa type IV collagenaseHomo sapiens (human)
metallopeptidase activity72 kDa type IV collagenaseHomo sapiens (human)
zinc ion binding72 kDa type IV collagenaseHomo sapiens (human)
protein bindingIntegrin alpha-IIbHomo sapiens (human)
identical protein bindingIntegrin alpha-IIbHomo sapiens (human)
metal ion bindingIntegrin alpha-IIbHomo sapiens (human)
extracellular matrix bindingIntegrin alpha-IIbHomo sapiens (human)
molecular adaptor activityIntegrin alpha-IIbHomo sapiens (human)
fibrinogen bindingIntegrin alpha-IIbHomo sapiens (human)
integrin bindingIntegrin alpha-IIbHomo sapiens (human)
serine-type endopeptidase activityComplement C1s subcomponentHomo sapiens (human)
calcium ion bindingComplement C1s subcomponentHomo sapiens (human)
protein bindingComplement C1s subcomponentHomo sapiens (human)
identical protein bindingComplement C1s subcomponentHomo sapiens (human)
endopeptidase activityMatrix metalloproteinase-9Homo sapiens (human)
metalloendopeptidase activityMatrix metalloproteinase-9Homo sapiens (human)
serine-type endopeptidase activityMatrix metalloproteinase-9Homo sapiens (human)
protein bindingMatrix metalloproteinase-9Homo sapiens (human)
collagen bindingMatrix metalloproteinase-9Homo sapiens (human)
peptidase activityMatrix metalloproteinase-9Homo sapiens (human)
metallopeptidase activityMatrix metalloproteinase-9Homo sapiens (human)
zinc ion bindingMatrix metalloproteinase-9Homo sapiens (human)
identical protein bindingMatrix metalloproteinase-9Homo sapiens (human)
endopeptidase activityNeutrophil collagenaseHomo sapiens (human)
metalloendopeptidase activityNeutrophil collagenaseHomo sapiens (human)
serine-type endopeptidase activityNeutrophil collagenaseHomo sapiens (human)
peptidase activityNeutrophil collagenaseHomo sapiens (human)
zinc ion bindingNeutrophil collagenaseHomo sapiens (human)
tumor necrosis factor bindingNeutrophil collagenaseHomo sapiens (human)
endopeptidase activityCollagenase 3Homo sapiens (human)
metalloendopeptidase activityCollagenase 3Homo sapiens (human)
serine-type endopeptidase activityCollagenase 3Homo sapiens (human)
calcium ion bindingCollagenase 3Homo sapiens (human)
collagen bindingCollagenase 3Homo sapiens (human)
zinc ion bindingCollagenase 3Homo sapiens (human)
protein bindingHepatocyte growth factor activatorHomo sapiens (human)
serine-type peptidase activityHepatocyte growth factor activatorHomo sapiens (human)
serine-type endopeptidase activityHepatocyte growth factor activatorHomo sapiens (human)
serine-type endopeptidase activitySuppressor of tumorigenicity 14 proteinHomo sapiens (human)
serine-type peptidase activitySuppressor of tumorigenicity 14 proteinHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (57)

Processvia Protein(s)Taxonomy
external side of plasma membraneProthrombinHomo sapiens (human)
collagen-containing extracellular matrixProthrombinHomo sapiens (human)
extracellular regionProthrombinHomo sapiens (human)
extracellular spaceProthrombinHomo sapiens (human)
endoplasmic reticulum lumenProthrombinHomo sapiens (human)
Golgi lumenProthrombinHomo sapiens (human)
plasma membraneProthrombinHomo sapiens (human)
extracellular exosomeProthrombinHomo sapiens (human)
blood microparticleProthrombinHomo sapiens (human)
collagen-containing extracellular matrixProthrombinHomo sapiens (human)
extracellular spaceProthrombinHomo sapiens (human)
extracellular regionComplement C1r subcomponentHomo sapiens (human)
extracellular spaceComplement C1r subcomponentHomo sapiens (human)
extracellular exosomeComplement C1r subcomponentHomo sapiens (human)
blood microparticleComplement C1r subcomponentHomo sapiens (human)
extracellular spaceComplement C1r subcomponentHomo sapiens (human)
extracellular regionCoagulation factor XHomo sapiens (human)
endoplasmic reticulum lumenCoagulation factor XHomo sapiens (human)
Golgi lumenCoagulation factor XHomo sapiens (human)
plasma membraneCoagulation factor XHomo sapiens (human)
external side of plasma membraneCoagulation factor XHomo sapiens (human)
extracellular spaceCoagulation factor XHomo sapiens (human)
extracellular regionPlasminogenHomo sapiens (human)
extracellular spacePlasminogenHomo sapiens (human)
plasma membranePlasminogenHomo sapiens (human)
external side of plasma membranePlasminogenHomo sapiens (human)
cell surfacePlasminogenHomo sapiens (human)
platelet alpha granule lumenPlasminogenHomo sapiens (human)
collagen-containing extracellular matrixPlasminogenHomo sapiens (human)
extracellular exosomePlasminogenHomo sapiens (human)
blood microparticlePlasminogenHomo sapiens (human)
Schaffer collateral - CA1 synapsePlasminogenHomo sapiens (human)
glutamatergic synapsePlasminogenHomo sapiens (human)
extracellular spacePlasminogenHomo sapiens (human)
extracellular regionCoagulation factor XIIHomo sapiens (human)
extracellular spaceCoagulation factor XIIHomo sapiens (human)
plasma membraneCoagulation factor XIIHomo sapiens (human)
collagen-containing extracellular matrixCoagulation factor XIIHomo sapiens (human)
extracellular exosomeCoagulation factor XIIHomo sapiens (human)
extracellular spaceCoagulation factor XIIHomo sapiens (human)
rough endoplasmic reticulumCoagulation factor XIIHomo sapiens (human)
serine protease inhibitor complexCationic trypsinBos taurus (cattle)
extracellular regionInterstitial collagenaseHomo sapiens (human)
extracellular matrixInterstitial collagenaseHomo sapiens (human)
extracellular spaceInterstitial collagenaseHomo sapiens (human)
glutamatergic synapseIntegrin beta-3Homo sapiens (human)
nucleusIntegrin beta-3Homo sapiens (human)
nucleoplasmIntegrin beta-3Homo sapiens (human)
plasma membraneIntegrin beta-3Homo sapiens (human)
cell-cell junctionIntegrin beta-3Homo sapiens (human)
focal adhesionIntegrin beta-3Homo sapiens (human)
external side of plasma membraneIntegrin beta-3Homo sapiens (human)
cell surfaceIntegrin beta-3Homo sapiens (human)
apical plasma membraneIntegrin beta-3Homo sapiens (human)
platelet alpha granule membraneIntegrin beta-3Homo sapiens (human)
lamellipodium membraneIntegrin beta-3Homo sapiens (human)
filopodium membraneIntegrin beta-3Homo sapiens (human)
microvillus membraneIntegrin beta-3Homo sapiens (human)
ruffle membraneIntegrin beta-3Homo sapiens (human)
integrin alphav-beta3 complexIntegrin beta-3Homo sapiens (human)
melanosomeIntegrin beta-3Homo sapiens (human)
synapseIntegrin beta-3Homo sapiens (human)
postsynaptic membraneIntegrin beta-3Homo sapiens (human)
extracellular exosomeIntegrin beta-3Homo sapiens (human)
integrin alphaIIb-beta3 complexIntegrin beta-3Homo sapiens (human)
glycinergic synapseIntegrin beta-3Homo sapiens (human)
integrin complexIntegrin beta-3Homo sapiens (human)
protein-containing complexIntegrin beta-3Homo sapiens (human)
alphav-beta3 integrin-PKCalpha complexIntegrin beta-3Homo sapiens (human)
alphav-beta3 integrin-IGF-1-IGF1R complexIntegrin beta-3Homo sapiens (human)
alphav-beta3 integrin-HMGB1 complexIntegrin beta-3Homo sapiens (human)
receptor complexIntegrin beta-3Homo sapiens (human)
alphav-beta3 integrin-vitronectin complexIntegrin beta-3Homo sapiens (human)
alpha9-beta1 integrin-ADAM8 complexIntegrin beta-3Homo sapiens (human)
focal adhesionIntegrin beta-3Homo sapiens (human)
cell surfaceIntegrin beta-3Homo sapiens (human)
synapseIntegrin beta-3Homo sapiens (human)
nuclear membraneSerine protease hepsinHomo sapiens (human)
endoplasmic reticulum membraneSerine protease hepsinHomo sapiens (human)
plasma membraneSerine protease hepsinHomo sapiens (human)
cell-cell junctionSerine protease hepsinHomo sapiens (human)
cell surfaceSerine protease hepsinHomo sapiens (human)
membraneSerine protease hepsinHomo sapiens (human)
apical plasma membraneSerine protease hepsinHomo sapiens (human)
neuronal cell bodySerine protease hepsinHomo sapiens (human)
extracellular exosomeSerine protease hepsinHomo sapiens (human)
collagen-containing extracellular matrixCathepsin DHomo sapiens (human)
extracellular regionCathepsin DHomo sapiens (human)
extracellular spaceCathepsin DHomo sapiens (human)
lysosomeCathepsin DHomo sapiens (human)
lysosomal membraneCathepsin DHomo sapiens (human)
endosome membraneCathepsin DHomo sapiens (human)
endosome lumenCathepsin DHomo sapiens (human)
specific granule lumenCathepsin DHomo sapiens (human)
melanosomeCathepsin DHomo sapiens (human)
lysosomal lumenCathepsin DHomo sapiens (human)
membrane raftCathepsin DHomo sapiens (human)
collagen-containing extracellular matrixCathepsin DHomo sapiens (human)
extracellular exosomeCathepsin DHomo sapiens (human)
tertiary granule lumenCathepsin DHomo sapiens (human)
ficolin-1-rich granule lumenCathepsin DHomo sapiens (human)
extracellular regionTrypsin-1Homo sapiens (human)
collagen-containing extracellular matrixTrypsin-1Homo sapiens (human)
blood microparticleTrypsin-1Homo sapiens (human)
extracellular spaceTrypsin-1Homo sapiens (human)
collagen-containing extracellular matrix72 kDa type IV collagenaseHomo sapiens (human)
extracellular region72 kDa type IV collagenaseHomo sapiens (human)
extracellular space72 kDa type IV collagenaseHomo sapiens (human)
nucleus72 kDa type IV collagenaseHomo sapiens (human)
mitochondrion72 kDa type IV collagenaseHomo sapiens (human)
plasma membrane72 kDa type IV collagenaseHomo sapiens (human)
sarcomere72 kDa type IV collagenaseHomo sapiens (human)
collagen-containing extracellular matrix72 kDa type IV collagenaseHomo sapiens (human)
extracellular space72 kDa type IV collagenaseHomo sapiens (human)
plasma membraneIntegrin alpha-IIbHomo sapiens (human)
focal adhesionIntegrin alpha-IIbHomo sapiens (human)
cell surfaceIntegrin alpha-IIbHomo sapiens (human)
platelet alpha granule membraneIntegrin alpha-IIbHomo sapiens (human)
extracellular exosomeIntegrin alpha-IIbHomo sapiens (human)
integrin alphaIIb-beta3 complexIntegrin alpha-IIbHomo sapiens (human)
blood microparticleIntegrin alpha-IIbHomo sapiens (human)
integrin complexIntegrin alpha-IIbHomo sapiens (human)
external side of plasma membraneIntegrin alpha-IIbHomo sapiens (human)
extracellular regionComplement C1s subcomponentHomo sapiens (human)
blood microparticleComplement C1s subcomponentHomo sapiens (human)
extracellular spaceComplement C1s subcomponentHomo sapiens (human)
extracellular regionMatrix metalloproteinase-9Homo sapiens (human)
extracellular spaceMatrix metalloproteinase-9Homo sapiens (human)
collagen-containing extracellular matrixMatrix metalloproteinase-9Homo sapiens (human)
extracellular exosomeMatrix metalloproteinase-9Homo sapiens (human)
tertiary granule lumenMatrix metalloproteinase-9Homo sapiens (human)
ficolin-1-rich granule lumenMatrix metalloproteinase-9Homo sapiens (human)
extracellular spaceMatrix metalloproteinase-9Homo sapiens (human)
extracellular regionNeutrophil collagenaseHomo sapiens (human)
extracellular spaceNeutrophil collagenaseHomo sapiens (human)
specific granule lumenNeutrophil collagenaseHomo sapiens (human)
collagen-containing extracellular matrixNeutrophil collagenaseHomo sapiens (human)
tertiary granule lumenNeutrophil collagenaseHomo sapiens (human)
extracellular spaceNeutrophil collagenaseHomo sapiens (human)
extracellular regionCollagenase 3Homo sapiens (human)
extracellular matrixCollagenase 3Homo sapiens (human)
extracellular spaceCollagenase 3Homo sapiens (human)
extracellular regionHepatocyte growth factor activatorHomo sapiens (human)
cytosolHepatocyte growth factor activatorHomo sapiens (human)
rough endoplasmic reticulumHepatocyte growth factor activatorHomo sapiens (human)
extracellular spaceHepatocyte growth factor activatorHomo sapiens (human)
extracellular spaceSuppressor of tumorigenicity 14 proteinHomo sapiens (human)
plasma membraneSuppressor of tumorigenicity 14 proteinHomo sapiens (human)
external side of plasma membraneSuppressor of tumorigenicity 14 proteinHomo sapiens (human)
basolateral plasma membraneSuppressor of tumorigenicity 14 proteinHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (77)

Assay IDTitleYearJournalArticle
AID1345994Human serine protease 1 (S1: Chymotrypsin)1998Journal of medicinal chemistry, Mar-26, Volume: 41, Issue:7
2-amino-4H-3,1-benzoxazin-4-ones as inhibitors of C1r serine protease.
AID1347014Human complement C1r (S1: Chymotrypsin)1998Journal of medicinal chemistry, Mar-26, Volume: 41, Issue:7
2-amino-4H-3,1-benzoxazin-4-ones as inhibitors of C1r serine protease.
AID1345995Human tryptase alpha/beta 1 (S1: Chymotrypsin)2003Journal of pharmacological sciences, Aug, Volume: 92, Issue:4
Nafamostat mesilate is an extremely potent inhibitor of human tryptase.
AID1346595Human TRPM7 (ChaK subfamily)2010Molecular brain, Dec-01, Volume: 3The modulation of TRPM7 currents by nafamostat mesilate depends directly upon extracellular concentrations of divalent cations.
AID1347411qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Mechanism Interrogation Plate v5.0 (MIPE) Libary2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID504749qHTS profiling for inhibitors of Plasmodium falciparum proliferation2011Science (New York, N.Y.), Aug-05, Volume: 333, Issue:6043
Chemical genomic profiling for antimalarial therapies, response signatures, and molecular targets.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347100qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1347101qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347096qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347089qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347090qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347095qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347098qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347091qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347094qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347107qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347102qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347105qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347093qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347103qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347108qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347099qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347092qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347106qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347104qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347097qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1495527Inhibition of recombinant C-terminal His10-tagged human Hepsin (R45 to L17 residues) D161E/ R162K double mutant expressed in mouse NS0 cells using Boc-QRR-AMC as substrate after 15 mins by automated fluorescence assay2018Journal of medicinal chemistry, 05-24, Volume: 61, Issue:10
Design, Synthesis, and Testing of Potent, Selective Hepsin Inhibitors via Application of an Automated Closed-Loop Optimization Platform.
AID1251261Antagonist activity against integrin alpha2bbeta3 in human platelet rich plasma2015Journal of medicinal chemistry, Oct-08, Volume: 58, Issue:19
Design, Virtual Screening, and Synthesis of Antagonists of αIIbβ3 as Antiplatelet Agents.
AID1409613Selectivity ratio: ratio of AUC (viral infection %) of SARS-CoV-2 in the Vero E6 cell line compared to AUC (cytotoxicity %) of compound against Vero E6 cells by MTT assay.2020Nature, 07, Volume: 583, Issue:7816
A SARS-CoV-2 protein interaction map reveals targets for drug repurposing.
AID211559Inhibitory concentration against thrombin2000Journal of medicinal chemistry, Feb-10, Volume: 43, Issue:3
Protease inhibitors: current status and future prospects.
AID1717749Cytotoxicity against African green monkey Vero E6 cells by the CCK8 assay2020Journal of medicinal chemistry, 11-25, Volume: 63, Issue:22
Chinese Therapeutic Strategy for Fighting COVID-19 and Potential Small-Molecule Inhibitors against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
AID50880Evaluated in vitro for inhibitory activity against purified human C1r protease incubated in buffer for 60 minutes1999Bioorganic & medicinal chemistry letters, Mar-22, Volume: 9, Issue:6
Benzenesulfonamide derivatives of 2-substituted 4H-3,1-benzoxazin-4-ones and benzthiazin-4-ones as inhibitors of complement C1r protease.
AID52486Inhibition of collagenase2000Journal of medicinal chemistry, Feb-10, Volume: 43, Issue:3
Protease inhibitors: current status and future prospects.
AID43030Inhibition of 50% of human C1r Serine Protease by initially using Cbz-Gly-Arg-S-Bzl as substrate1998Journal of medicinal chemistry, Mar-26, Volume: 41, Issue:7
2-amino-4H-3,1-benzoxazin-4-ones as inhibitors of C1r serine protease.
AID48013Inhibitory concentration against cathepsin2000Journal of medicinal chemistry, Feb-10, Volume: 43, Issue:3
Protease inhibitors: current status and future prospects.
AID1705173Inhibition of bovine trypsin using chromogenic substrate by Lineweaver-Burk analysis2020European journal of medicinal chemistry, Dec-15, Volume: 208Factor XII/XIIa inhibitors: Their discovery, development, and potential indications.
AID1195360Inhibition of recombinant N-terminal His-tagged HGFA (unknown origin) expressed in baculovirus-infected Sf9 cells incubated for 30 mins prior to cromogenic substrate addition by spectrophotometry2015Bioorganic & medicinal chemistry, May-15, Volume: 23, Issue:10
Structure-based discovery of small molecule hepsin and HGFA protease inhibitors: Evaluation of potency and selectivity derived from distinct binding pockets.
AID1171339Inhibition of recombinant HGFA (unknown origin) using Boc-QLR-AMC as substrate by chromogenic proteolytic assay2014ACS medicinal chemistry letters, Nov-13, Volume: 5, Issue:11
Inhibitors of HGFA, Matriptase, and Hepsin Serine Proteases: A Nonkinase Strategy to Block Cell Signaling in Cancer.
AID1409608AUC (viral infection %) for SARS-CoV-2 in the Vero E6 cell line at 48 h by immunofluorescence-based assay (detecting the viral NP protein in the nucleus of the Vero E6 cells).2020Nature, 07, Volume: 583, Issue:7816
A SARS-CoV-2 protein interaction map reveals targets for drug repurposing.
AID43179inhibition against the production of C3a and C5a generated by C3/C5 Convertase at 4.0 uM2000Journal of medicinal chemistry, Feb-10, Volume: 43, Issue:3
Protease inhibitors: current status and future prospects.
AID51836Inhibitory concentration against Coagulation factor X2000Journal of medicinal chemistry, Feb-10, Volume: 43, Issue:3
Protease inhibitors: current status and future prospects.
AID1171348Inhibition of HGFA in human MDA-MB-231 cells assessed as inhibition of c-MET phosphorylation after 15 mins by immunoblotting2014ACS medicinal chemistry letters, Nov-13, Volume: 5, Issue:11
Inhibitors of HGFA, Matriptase, and Hepsin Serine Proteases: A Nonkinase Strategy to Block Cell Signaling in Cancer.
AID215021In vitro for inhibition of purified bovine trypsin.1999Bioorganic & medicinal chemistry letters, Mar-22, Volume: 9, Issue:6
Benzenesulfonamide derivatives of 2-substituted 4H-3,1-benzoxazin-4-ones and benzthiazin-4-ones as inhibitors of complement C1r protease.
AID1393212Inhibition of human serum C1s using AGLME as substrate after 30 mins2018Journal of medicinal chemistry, 04-26, Volume: 61, Issue:8
Chemical Approaches to Modulating Complement-Mediated Diseases.
AID225429Inhibitory concentration against plasmin2000Journal of medicinal chemistry, Feb-10, Volume: 43, Issue:3
Protease inhibitors: current status and future prospects.
AID1393211Inhibition of human serum C1r using AAME as substrate after 30 mins2018Journal of medicinal chemistry, 04-26, Volume: 61, Issue:8
Chemical Approaches to Modulating Complement-Mediated Diseases.
AID1558664Inhibition of human plasmin assessed as reduction in hydrolytic activity using TAME as substrate after 5 mins by spectrophotometric method2020Journal of medicinal chemistry, 02-27, Volume: 63, Issue:4
Fibrinolysis Inhibitors: Potential Drugs for the Treatment and Prevention of Bleeding.
AID1495528Inhibition of recombinant C-terminal His10-tagged human uPA (M1 to L431 residues) expressed in mouse NS0 cells using Z-GGR-AMC as substrate after 15 mins by automated fluorescence assay2018Journal of medicinal chemistry, 05-24, Volume: 61, Issue:10
Design, Synthesis, and Testing of Potent, Selective Hepsin Inhibitors via Application of an Automated Closed-Loop Optimization Platform.
AID1810151Inhibition of pro-HGF stimulated cell growth in human H596 cells at 33.3 uM by ELISA2021Journal of medicinal chemistry, 12-23, Volume: 64, Issue:24
Macrocyclic Inhibitors of HGF-Activating Serine Proteases Overcome Resistance to Receptor Tyrosine Kinase Inhibitors and Block Lung Cancer Progression.
AID43031The compound was evaluated to inhibit 50% of Clr Serine Protease after 60 mins and is expressed in IC50 (uM).1998Journal of medicinal chemistry, Mar-26, Volume: 41, Issue:7
2-amino-4H-3,1-benzoxazin-4-ones as inhibitors of C1r serine protease.
AID1409611AUC (cytotoxicity %) of compound against Vero E6 cells by MTT assay.2020Nature, 07, Volume: 583, Issue:7816
A SARS-CoV-2 protein interaction map reveals targets for drug repurposing.
AID1409609Cytotoxicity of compound against Vero E6 cells by MTT assay.2020Nature, 07, Volume: 583, Issue:7816
A SARS-CoV-2 protein interaction map reveals targets for drug repurposing.
AID1717750Selectivity index, ratio of CC50 for African green monkey Vero E6 cells to EC50 for 2019-nCoV Beta CoV/Wuhan/WIV04/2019 infected in African green monkey Vero E6 cells2020Journal of medicinal chemistry, 11-25, Volume: 63, Issue:22
Chinese Therapeutic Strategy for Fighting COVID-19 and Potential Small-Molecule Inhibitors against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
AID1195363Inhibition of hepsin (unknown origin) using Boc-QAR-AMC as substrate after 30 mins prior to substrate addition by fluorescence assay2015Bioorganic & medicinal chemistry, May-15, Volume: 23, Issue:10
Structure-based discovery of small molecule hepsin and HGFA protease inhibitors: Evaluation of potency and selectivity derived from distinct binding pockets.
AID1171340Inhibition of matriptase (unknown origin) using Boc-QAR-AMC as substrate by fluorescence assay2014ACS medicinal chemistry letters, Nov-13, Volume: 5, Issue:11
Inhibitors of HGFA, Matriptase, and Hepsin Serine Proteases: A Nonkinase Strategy to Block Cell Signaling in Cancer.
AID203031Compound was evaluated for inhibitory activity in hemolysis assay using suspension of sheep erythrocytes sensitized with antibodies to sheep erythrocytes1999Bioorganic & medicinal chemistry letters, Mar-22, Volume: 9, Issue:6
Benzenesulfonamide derivatives of 2-substituted 4H-3,1-benzoxazin-4-ones and benzthiazin-4-ones as inhibitors of complement C1r protease.
AID1480447Antagonist activity at integrin alpha2b beta3 receptor in citrated human platelet-rich plasma assessed as inhibition of ADP-induced platelet aggregation2017Journal of medicinal chemistry, 04-27, Volume: 60, Issue:8
Emergence of Small-Molecule Non-RGD-Mimetic Inhibitors for RGD Integrins.
AID50879In vitro inhibition of purified human C1r protease.1999Bioorganic & medicinal chemistry letters, Mar-22, Volume: 9, Issue:6
Benzenesulfonamide derivatives of 2-substituted 4H-3,1-benzoxazin-4-ones and benzthiazin-4-ones as inhibitors of complement C1r protease.
AID1409607IC50 for antiviral activity against SARS-CoV-2 in the Vero E6 cell line at 48 h by immunofluorescence-based assay (detecting the viral NP protein in the nucleus of the Vero E6 cells).2020Nature, 07, Volume: 583, Issue:7816
A SARS-CoV-2 protein interaction map reveals targets for drug repurposing.
AID1717748Antiviral activity against 2019-nCoV BetaCoV/Wuhan/WIV04/2019 infected in African green monkey VeroE6 cells assessed as reduction in viral yield preincubated with virus for 1 hr followed by cell infection and measured after 2 hrs by qRT-PCR method2020Journal of medicinal chemistry, 11-25, Volume: 63, Issue:22
Chinese Therapeutic Strategy for Fighting COVID-19 and Potential Small-Molecule Inhibitors against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
AID1195362Inhibition of matripase (unknown origin) using Boc-QAR-AMC as substrate incubated for 30 mins prior to substrate addition by fluorescence assay2015Bioorganic & medicinal chemistry, May-15, Volume: 23, Issue:10
Structure-based discovery of small molecule hepsin and HGFA protease inhibitors: Evaluation of potency and selectivity derived from distinct binding pockets.
AID1195361Inhibition of recombinant N-terminal His-tagged HGFA (unknown origin) expressed in baculovirus-infected Sf9 cells using Boc-QLR-AMC as substrate incubated for 30 mins prior to substrate addition by fluorescence assay2015Bioorganic & medicinal chemistry, May-15, Volume: 23, Issue:10
Structure-based discovery of small molecule hepsin and HGFA protease inhibitors: Evaluation of potency and selectivity derived from distinct binding pockets.
AID1171341Inhibition of recombinant hepsin (unknown origin) using Boc-QAR-AMC as substrate by fluorescence assay2014ACS medicinal chemistry letters, Nov-13, Volume: 5, Issue:11
Inhibitors of HGFA, Matriptase, and Hepsin Serine Proteases: A Nonkinase Strategy to Block Cell Signaling in Cancer.
AID1705180Inhibition of human factor 12a using chromogenic substrate by Lineweaver-Burk analysis2020European journal of medicinal chemistry, Dec-15, Volume: 208Factor XII/XIIa inhibitors: Their discovery, development, and potential indications.
AID1409614Overall antiviral activity against SARS-CoV-2 (isolate France/IDF0372/2020) in the Vero E6 cell line at 48 h based on three assays 1) detection of viral RNA by qRT-PCR (targeting the N-gene), 2) plaque assay using lysate 3 days after addition of compound 2020Nature, 07, Volume: 583, Issue:7816
A SARS-CoV-2 protein interaction map reveals targets for drug repurposing.
AID215034The compound was evaluated to inhibit trypsin and is expressed in IC50 (The concentration required to inhibit 50% of the enzyme).1998Journal of medicinal chemistry, Mar-26, Volume: 41, Issue:7
2-amino-4H-3,1-benzoxazin-4-ones as inhibitors of C1r serine protease.
AID1745855NCATS anti-infectives library activity on the primary C. elegans qHTS viability assay2023Disease models & mechanisms, 03-01, Volume: 16, Issue:3
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
AID1745854NCATS anti-infectives library activity on HEK293 viability as a counter-qHTS vs the C. elegans viability qHTS2023Disease models & mechanisms, 03-01, Volume: 16, Issue:3
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (604)

TimeframeStudies, This Drug (%)All Drugs %
pre-199059 (9.77)18.7374
1990's190 (31.46)18.2507
2000's144 (23.84)29.6817
2010's112 (18.54)24.3611
2020's99 (16.39)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 42.14

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index42.14 (24.57)
Research Supply Index6.54 (2.92)
Research Growth Index4.94 (4.65)
Search Engine Demand Index64.87 (26.88)
Search Engine Supply Index1.98 (0.95)

This Compound (42.14)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials54 (8.44%)5.53%
Reviews52 (8.13%)6.00%
Case Studies77 (12.03%)4.05%
Observational4 (0.63%)0.25%
Other453 (70.78%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (17)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
A Multi-centre Randomised Adaptive Platform Clinical Trial to Assess Clinical, Virological and Immunological Outcomes in Patients With SARS-CoV-2 Infection (COVID-19) [NCT04483960]Phase 32,400 participants (Anticipated)Interventional2020-07-28Recruiting
[NCT02478242]Phase 460 participants (Actual)Interventional2010-07-31Completed
A Single Dose Study to Evaluate the Pharmacokinetics of Oxycodone and PF614 When PF614 Solution is Co-Administered With Nafamostat, as an Immediate Release Solution and/or Extended Release (ER) Capsule Formulations in Healthy Subjects [NCT05090280]Phase 1111 participants (Actual)Interventional2021-12-01Active, not recruiting
An Open-label, Randomized, Multicenter, Controlled Clinical Trial to Evaluate the Efficacy and Safety of CKD-314 (Nafabelltan) in Hospitalized Adult Patients Diagnosed With COVID-19 Pneumonia [NCT04623021]Phase 2104 participants (Actual)Interventional2020-09-25Completed
The Safety of Nafamostat Mesylate for Patients With High Risk Bleeding Diathesis Undergoing Hemodialysis: A Pilot Study [NCT05874674]100 participants (Anticipated)Interventional2023-12-01Enrolling by invitation
Open-label, Multi-center, Randomized Controlled, Phase 2 Clinical Trial to Evaluate the Efficacy and Safety of CKD-314 in Hospitalized Adult Patients Diagnosed With COVID-19 [NCT04628143]Phase 213 participants (Actual)Interventional2020-12-21Completed
Nafamostat Mesilate in the Treatment of Severe Infection-associated Coagulopathy: a Multicenter Randomized Controlled Trial [NCT06078839]Phase 4778 participants (Anticipated)Interventional2023-10-01Not yet recruiting
Effect of Nafamostat Mesilate on Hemodynamic Stability After Reperfusion of the Liver Graft [NCT01001403]Phase 462 participants (Actual)Interventional2009-03-31Completed
DEFINE - Evaluating Therapies for COVID-19 [NCT04473053]Phase 1/Phase 2200 participants (Anticipated)Interventional2020-07-03Recruiting
A Single-Center, Double-Blind, Placebo-Controlled, Phase 1b Multiple Ascending Dose Study to Investigate the Safety, Tolerability, and Pharmacokinetics of Sequential Dose Regimens of Oral Nafamostat Mesylate in Healthy Volunteers Subjects [NCT04406415]Phase 117 participants (Actual)Interventional2020-09-21Completed
Circuit Survival and Efficacy for Middle Molecular-weight Solute Elimination Between Nafamostat Infusion and Heparinized Saline Priming [NCT01486485]Phase 3160 participants (Anticipated)Interventional2012-03-31Recruiting
[NCT01761994]Phase 466 participants (Actual)Interventional2007-09-30Completed
Multicentre, Open Label, Randomised, Adaptative Clinical Trial of Efficacy and Safety of Treatment Regimens in Adult COVID-19 Patients in Senegal [NCT04390594]Phase 3186 participants (Anticipated)Interventional2020-08-13Recruiting
A Double-blind, Multi-center, Multi-regional, Randomized Controlled, Phase 3 Clinical Trial to Evaluate the Efficacy and Safety of CKD-314 in Hospitalized Adult Patients Diagnosed With COVID-19 [NCT04871646]Phase 3586 participants (Anticipated)Interventional2021-06-30Recruiting
Efficacy and Safety of Nafamostat Mesylate for VV-ECMO Anticoagulation: a Randomized, Single-blind, Multicenter Exploratory, Heparin-controlled Trial [NCT05555641]Phase 240 participants (Anticipated)Interventional2022-12-20Recruiting
RAndomized Clinical Trial in COvid19 Patients to Assess the Efficacy of the Transmembrane Protease Serine 2 (TMPRSS2) Inhibitor NAfamostat (RACONA Study) [NCT04352400]Phase 2/Phase 3256 participants (Anticipated)Interventional2021-06-04Recruiting
Treatment Effect of Nafamostat Mesylate in Patients With COVID-19 Pneumonia: Open Labelled Randomized Controlled Clinical Trial [NCT04418128]Phase 2/Phase 384 participants (Anticipated)Interventional2020-06-10Not yet recruiting
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

TrialOutcome
NCT01001403 (1) [back to overview]Number of Participants With Moderate and Severe Postreperfusion Syndrome (PRS)

Number of Participants With Moderate and Severe Postreperfusion Syndrome (PRS)

"Before entering the study, we re-defined the criteria of PRS. From our clinical experiences, two types of PRS were observed according to its severity and treatment option. Moderate PRS was identical to previously defined PRS: more than 30% decrease of mean arterial pressure lasting over 1 min was observed within 5 min after reperfusion of the liver graft. However, we differentiated a severe form of PRS, in which MAP rapidly fell below 40 mmHg, from the moderate one, because severe PRS required prompt intervention to prevent a permanent damage of vital organs." (NCT01001403)
Timeframe: during 5 min after reperfusion of liver graft

Interventionparticipants (Number)
Nafamostat15
Control25

[back to top]